Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 4Phase 1 2Phase NA 1Phase 1/2 1

Status

Active not recruiting 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 9Small Cell Lung Carcinoma 7Biliary Tract Neoplasms 7Carcinoma, Hepatocellular 6Urinary Bladder Neoplasms 4Liver Neoplasms 4Carcinoma 4Neoplasm Metastasis 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma Extensive Disease 2Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Non-Muscle Invasive Bladder Neoplasms 2Gallbladder Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Urothelial Cancer 1Sarcoma 1Radiation Pneumonitis 1Pancoast Syndrome 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Non Small Cell Lung Carcinoma NSCLC 1Non Small Cell Lung Cancer NSCLC 1Non - Small Cell Lung Cancer NSCLC 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1

Interventions

Sorafenib 8durvalumab 4Cisplatin 4Gemcitabine 3Ethiodized Oil 3Doxorubicin 3Chemotherapy, Adjuvant 3Bevacizumab 3tremelimumab 2sodium thiosulfate 2phosphomannopentaose sulfate 2Watchful Waiting 2Talaporfin 2Radiofrequency Ablation 2Oxaliplatin 2Nivolumab 2Folfox protocol 2Celecoxib 2Capecitabine 2Analgesia, Patient-Controlled 2seocalcitol 1parecoxib 1nolatrexed 1linifanib 1lenvatinib 1ferumoxides 1ferric carboxymaltose 1contrast agent BR1 1cabozantinib 1brivanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Liver Neoplasms × durvalumab × Clear all
NCT05883644 2026-04-30

SIERRA

AstraZeneca

Phase 3 Active not recruiting
111 enrolled
Gastrointestinal

Liver Neoplasms

NCT03778957 2026-04-15

EMERALD-1

AstraZeneca

Phase 3 Active not recruiting
724 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05301842 2026-04-07

EMERALD-3

AstraZeneca

Phase 3 Active not recruiting
760 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03847428 2026-03-06

EMERALD-2

AstraZeneca

Phase 3 Active not recruiting
908 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡